Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

Abstract Heart failure (HF) is a major public health problem characterised by high rate of hospitalisation and death. The risk maximal for patients admitted with acute heart (AHF). New therapies solid proof mortality reduction in both groups reduced preserved ejection fraction (EF) are now available (valsartan/sacubitril SGLT 2 inhibitors). purpose this article to review the main data clarify role these new AHF. precise moment initiating still matter debate. This paper presents recommended criteria clinical stability that clinician could use deciding initiate therapy. There growing amount evidence sooner provides more benefits patients.